DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Active, not recruiting	Phase 1	2026-09-24		NCT03716180

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Breast Cancer Research Foundation	40
Dana-Farber Cancer Institute	324
Susan G. Komen Breast Cancer Foundation	16
Terri Brodeur Breast Cancer Foundation	2

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Beth Israel Deaconess Medical Center	Boston	United States	462
Dana-Farber Cancer Institute	Boston	United States	626
DF/BWCC at Milford Regional Medical Center	Milford	United States	4
DF/BWCC in clinical affiliation with South Shore Hospital	South Weymouth	United States	5
Massachusetts General Hospital	Boston	United States	1015